For roughly four in every ten women whose estrogen receptor-positive breast cancer has spread and stopped responding to hormone-blocking drugs, the culprit is a genetic mutation that lets the tumor keep growing even without estrogen. Until now, the main fallback was fulvestrant, an injectable drug that partially breaks down the rogue receptor but often loses the race against the cancer’s evolving biology. In May 2026, the FDA approved a pill called vepdegestrant, sold as Veppanu, that takes a fundamentally different approach: it hijacks the cell’s own protein-recycling machinery to destroy the estrogen receptor entirely, rather than simply blocking it.
The approval makes vepdegestrant the first drug built on a technology known as PROTAC (proteolysis-targeting chimera) to clear the FDA, a milestone that researchers and pharmaceutical companies have chased for more than a decade. It is indicated for adults with ER-positive, HER2-negative advanced or metastatic breast cancer that carries ESR1 mutations and has progressed on at least one prior endocrine therapy.
How the drug turns a tumor’s fuel into a kill signal
Most breast cancers depend on estrogen. The hormone binds to estrogen receptors inside tumor cells, switching on the signals that drive growth. Standard endocrine therapies either block that receptor or cut off the estrogen supply. The strategy works for many patients, but over time a significant share of advanced tumors develop ESR1 mutations that allow the receptor to fire on its own, with no estrogen needed. When that happens, older drugs lose much of their power.
Vepdegestrant was designed to solve that problem at the molecular level. The drug is a two-headed molecule: one end grabs the estrogen receptor, and the other end recruits an E3 ligase, a cellular enzyme that tags proteins for disposal. Once both ends latch on, the cell’s proteasome, its built-in shredder for unwanted proteins, chews up the receptor and eliminates it. Blocking a mutated receptor still leaves it intact and capable of signaling through back-door pathways. Degrading it removes the target from the cell altogether.
The underlying science traces back to the lab of Craig Crews, a Yale University chemist who pioneered the PROTAC concept in the early 2000s and co-founded Arvinas, the biotech company that developed vepdegestrant. Yale described the approval as the first time a PROTAC-based therapy has reached patients through a regulatory green light. Independent analysis in Nature Reviews Drug Discovery echoed that assessment, noting the clearance opens a broader pipeline of targeted protein degradation drugs aimed at cancers and other diseases.
The clinical evidence behind the approval
The FDA based its decision on VERITAC-2, a phase 3, randomized, open-label trial that tested vepdegestrant head-to-head against fulvestrant in patients with ER-positive, HER2-negative advanced breast cancer. The study prespecified a biomarker-defined population of patients whose tumors carried ESR1 mutations, the group that ultimately defines the approved indication. The trial registration on ClinicalTrials.gov confirms the design, treatment arms, and primary endpoint of progression-free survival as assessed by blinded independent central review.
Peer-reviewed results were published in The New England Journal of Medicine, reporting efficacy and safety data including progression-free survival, objective response rates, and rates of grade 3 or higher adverse events. In the ESR1-mutated subgroup, vepdegestrant showed a statistically significant improvement in progression-free survival over fulvestrant, the result that drove the FDA’s benefit-risk conclusion.
The FDA’s approval announcement specifically labeled vepdegestrant a “heterobifunctional protein degrader,” a technical designation that distinguishes it from fulvestrant, which relies on conformational changes to trigger only partial receptor breakdown. Side effects observed in the trial were consistent with the drug class and included fatigue, nausea, diarrhea, and laboratory abnormalities. The agency concluded that the benefit in delaying disease progression outweighed those risks.
Who qualifies and what the drug means day to day
The approved label is narrow. Patients must have ER-positive, HER2-negative advanced or metastatic breast cancer, a confirmed ESR1 mutation, and documented progression on at least one endocrine therapy. Confirming the mutation typically requires a circulating tumor DNA (liquid biopsy) test or a tissue biopsy, a companion-diagnostic step that adds time and cost but is increasingly routine in precision oncology.
ESR1 mutations are not rare in this setting. Published estimates suggest they appear in roughly 30 to 40 percent of patients with ER-positive metastatic breast cancer who have been treated with aromatase inhibitors, meaning a substantial number of women could be candidates if testing is performed.
On a practical level, the oral formulation is a significant change from fulvestrant, which requires intramuscular injections on a recurring schedule that many patients find painful and inconvenient. A daily pill taken at home can reduce clinic visits and offer more flexibility, though it also shifts responsibility to patients for consistent adherence and monitoring.
Pricing and insurance coverage details had not been finalized in public disclosures as of late May 2026. Arvinas, which developed the drug in partnership with Pfizer for commercialization, has not yet published a list price. For patients and oncologists, cost will be a critical variable, especially in health systems where newer targeted therapies can carry substantial out-of-pocket burdens.
What is still unknown
Several important questions remain open. Overall survival data from VERITAC-2, the measure that tells patients whether a drug helps them live longer rather than just delaying tumor growth on a scan, have not yet matured. Long-term durability of response in the ESR1-mutated cohort and patient-reported quality-of-life outcomes also remain unreported in public registries.
How resistance to vepdegestrant will emerge is another unanswered question. Targeted therapies often work well initially but lose effectiveness as tumors evolve. Early laboratory work suggests that alterations in the proteasome pathway or in the binding sites the PROTAC molecule uses could reduce the drug’s impact, but real-world resistance patterns will only become clear with broader use and longer follow-up.
Full prescribing information, including drug-interaction tables and dose-modification guidance, is available through the FDA’s drug database. Patients on complex medication regimens should review the complete label with their oncologist, particularly those with liver impairment or other conditions that could affect how the drug is metabolized.
Where vepdegestrant fits in the treatment landscape
For women with ESR1-mutated metastatic breast cancer who have already progressed on endocrine therapy, the practical first step is a conversation with their oncologist about mutation testing if it has not already been done. If a mutation is confirmed, vepdegestrant may become an option at the current line of treatment or at the next progression point, depending on the individual’s history with endocrine agents, CDK4/6 inhibitors, and other targeted drugs.
Oncologists will weigh the magnitude of benefit over fulvestrant in the ESR1-mutated population, the patient’s tolerability profile, comorbid conditions, and preferences around oral versus injectable treatment. As longer follow-up data from VERITAC-2 and real-world evidence accumulate, the field will gain a sharper picture of where the drug belongs in the treatment sequence and whether combining it with other agents can extend its usefulness.
None of that diminishes what the approval represents right now. A protein that was once considered difficult to fully eliminate from cancer cells can now be tagged for destruction by a pill. For patients running out of options against a mutation that has outsmarted older therapies, that is not just a scientific milestone. It is a new line of defense.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
